Global Health Updates: From Bird Flu in New Zealand to Drug Developments in India
A series of notable health-related stories have emerged this week. In New Zealand, the H5N1 bird flu has…
This 7% Yielding Healthcare Powerhouse Belongs in Retirees’ Portfolios
Quick Read PFE’s 7.27% yield looks safe on a 53% adjusted payout ratio, but free cash flow fell…
The next goal for weight loss drugs? Fewer injections
For millions of people taking weight loss drugs, the next breakthrough may not be more weight loss. It…
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
Chai Discovery cofounders Josh Meier (left) and Jack Dent Cody Pickens for Forbes L ast June, when AI…
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Investors seeking reliable dividends and healthcare exposure often find themselves choosing between AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE). Both…
This Healthcare Stock With 6%-Plus Yield: Is the Dividend Safe?
Pfizer (NYSE: PFE) is facing patent expirations for some of its biggest drugs. That’s normal for a pharmaceutical…
The Most Important Healthcare Stock You’re Not Watching
A company with a $140 billion market cap is very large. It is also highly likely to be…
Could Buying This Beaten-Down Healthcare Stock Make You Rich If It Recovers?
Pfizer (NYSE: PFE) is in a difficult spot right now. It has a number of blockbuster drugs nearing…
How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story
In early May 2026, Pfizer reported first-quarter revenue of US$14.45 billion and net income of US$2.69 billion, with earnings per…
Which Healthcare Giant Is the Better Bet?
Novo Nordisk NVO and Pfizer PFE are both pharmaceutical giants based in Denmark and the United States, respectively, with…
Johnson & Johnson Vs. Pfizer
As large tech companies struggled this year, investors have had a chance to reevaluate their portfolios and identify…
The Best Healthcare Stocks to Buy With $50 Right Now
It’s not hard to find healthcare stocks, including small-cap biotech companies, trading below $50 per share. However, many…